Referências

1. Markham M.J., Wachter K., Agarwal N., Et al., Clinical cancer advances 2020: Annual report on progress against cancer from the American Society of Clinical oncology, J Clin Oncol, 38, pp. 1081-1101, (2020)
2. Puxty K., McLoone P., Quasim T., Sloan B., Kinsella J., Morrison D.S., Risk of critical illness among patients with solid cancers: A population-based observational study, JAMA Oncol, 1, pp. 1078-1085, (2015)
3. Sauer C.M., Dong J., Celi L.A., Ramazzotti D., Improved survival of cancer patients admitted to the intensive care unit between 2002 and 2011 at a U.S. Teaching Hospital, Cancer Res Treat, 51, pp. 973-981, (2019)
4. Bos M.M.E.M., De Keizer N.F., Meynaar I.A., Bakhshi-Raiez F., De Jonge E., Outcomes of cancer patients after unplanned admission to general intensive care units, Acta Oncol (Madr), 51, pp. 897-905, (2012)
5. Tan A.C., Jacques S.K., Oatley M., Guminski A.D., Characteristics and out­comes of oncology unit patients requiring admission to an Australian intensive care unit, Intern Med J, 49, pp. 734-739, (2019)
6. Lee D.S., Suh G.Y., Ryu J.A., Chung C.R., Yang J.H., Park C.M., Jeon K., Effect of early intervention on long-term outcomes of critically ill cancer patients admitted to ICUs, Crit Care Med, 43, pp. 1439-1448, (2015)
7. Mokart D., Lambert J., Schnell D., Et al., Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure, Leuk Lymphoma, 54, pp. 1724-1729, (2013)
8. Mokart D., Darmon M., Resche-Rigon M., Et al., Prognosis of neutropenic patients admitted to the intensive care unit, Intensive Care Med, 41, pp. 296-303, (2015)
9. Brenner H., Hakulinen T., Long-term cancer patient survival achieved by the end of the 20th century: Most up-to-date estimates from the nation­wide Finnish cancer registry, Br J Cancer, 85, pp. 367-371, (2001)
10. Maringe C., Belot A., Rachet B., Prediction of cancer survival for cohorts of patients most recently diagnosed using multi-model inference, Stat Methods Med Res, 29, pp. 3605-3622, (2020)
11. Esposito M., Ganesan S., Kang Y., Emerging strategies for treating metas­tasis, Nat Cancer, 2, pp. 258-270, (2021)
12. Bassford C., Decisions regarding admission to the ICU and international initiatives to improve the decision-making process, Crit Care, 21, pp. 1-3, (2017)
13. Dao L., Ragoonanan D., Yi S., Swinford R., Petropoulos D., Mahadeo K.M., Li S., The organ trail: A review of biomarkers of organ failure, Front Oncol, 10, pp. 1-10, (2020)
14. Feliu J., Heredia-Soto V., Girones R., Jimenez-Munarriz B., Saldana J., Guillen-Ponce C., Molina-Garrido M.J., Can we avoid the toxicity of che­motherapy in elderly cancer patients?, Crit Rev Oncol Hematol, 131, pp. 1-26, (2018)
15. Liu J., Pandya P., Afshar S., Therapeutic advances in oncology, Int J Mol Sci, 22, pp. 1-39, (2021)
16. Silbermann M., Pitsillides B., Al-Alfi N., Et al., Multidisciplinary care team for cancer patients and its implementation in several middle Eastern countries, Ann Oncol, 23, pp. 1-7, (2013)
17. Robert R., Reignier J., Tournoux-Facon C., Boulain T., Lesieur O., Gissot V., Souday V., Hamrouni M., Chapon C., Gouello J.P., Refusal of intensive care unit admission due to a full unit: Impact on mortality, Am J Respir Crit Care Med, 185, pp. 1081-1087, (2012)
18. Murthy S., Leligdowicz A., Adhikari N.K.J., Intensive care unit capacity in low-income countries: A systematic review, Plos One, 10, pp. 1-12, (2015)
19. Cardoso L.T.Q., Grion C.M.C., Matsuo T., Anami E.H.T., Kauss I.A.M., Seko L., Bonametti A.M., Impact of delayed admission to intensive care units on mortality of critically ill patients: A cohort study, Crit Care, 15, pp. 1-8, (2011)
20. Azoulay E., Mokart D., Kouatchet A., Demoule A., Lemiale V., Acute respiratory failure in immunocompromised adults, Lancet Respir Med, 7, pp. 173-186, (2019)
21. Chi A.K., Soubani A.O., White A.C., Miller K.B., An update on pulmonary complications of hematopoietic stem cell transplantation, Recent Adv Chest Med, 144, pp. 1913-1922, (2013)
22. Soares M., Depuydt P.O., Salluh J.I.F., Mechanical ventilation in cancer patients: Clinical characteristics and outcomes, Crit Care Clin, 26, pp. 41-58, (2010)
23. Cesar B.N., De Souza D.M., Acute kidney injury in cancer patients, Rev Assoc Med Bras, 66, pp. 25-30, (2020)
24. Salahudeen A.K., Doshi S.M., Pawar T., Nowshad G., Lahoti A., Shah P., Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center, Clin J am Soc Nephrol, 8, pp. 347-354, (2013)
25. Pitello N., Treon M., Jones K., Kiel P., Approaches for administering che­motherapy in the intensive care unit, Curr Drug Saf, 5, pp. 22-32, (2010)
26. Pearce A., Haas M., Viney R., Pearson S., Haywood P., Brown C., Ward R., Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study, Plos One, 12, pp. 1-12, (2017)
27. Akhlaghi E., Lehto R.H., Torabikhah M., Sharif Nia H., Taheri A., Zaboli E., Yaghoobzadeh A., Chemotherapy use and quality of life in cancer patients at the end of life: An integrative review, Health Qual Life Outcomes, 18, pp. 1-9, (2020)
28. Gudiol C., Albasanz-Puig A., Cuervo G., Carratala J., Understanding and managing sepsis in patients with cancer in the era of antimicrobial resis­tance, Front Med, 8, pp. 1-15, (2021)
29. Rosolem M.M., Rabello L.S.C.F., Lisboa T., Caruso P., Costa R.T., Leal J.V.R., Salluh J.I.F., Soares M., Critically ill patients with cancer and sepsis: Clin­ical course and prognostic factors, J Crit Care, 27, pp. 301-307, (2012)
30. Taberna M., Gil Moncayo F., Jane-Salas E., Antonio M., Arribas L., Vilajosana E., Peralvez Torres E., Mesia R., The multidisciplinary team (MDT) approach and quality of care, Front Oncol, 10, pp. 1-16, (2020)
31. Soares M., Bozza F.A., Azevedo L.C.P., Et al., Effects of organizational char­acteristics on outcomes and resource use in patients with cancer admit­ted to intensive care units, J Clin Oncol, 34, pp. 3315-3324, (2016)
32. Wang Y., Dai Y., Lau A.H., Yang J., Chen W., Li G., Oncology clinical pharmacy services in Chinese hospitals, J am Coll Clin Pharm, 3, pp. 988-996, (2020)
33. Coutsouvelis J., Adams J., Bortz H., Et al., Standard of practice in oncol­ogy and haematology for pharmacy services, J Pharm Pract Res, 50, pp. 528-545, (2020)
34. Holle L.M., Segal E.M., Jeffers K.D., The expanding role of the oncology pharmacist, Pharmacy, 8, pp. 1-5, (2020)
35. Moukafih B., Abahssain H., Mrabti H., Errihani H., Rahali Y., Taoufik J., Chaibi A., Impact of clinical pharmacy services in a hematology/oncol- ogy ward in Morocco, J Oncol Pharm Pract, 27, pp. 305-311, (2020)
36. Delpeuch A., Leveque D., Gourieux B., Herbrecht R., Impact of clinical pharmacy services in a hematology/oncology inpatient setting, Anticancer Res, 35, pp. 457-460, (2015)
37. Lin G., Huang R., Zhang J., Li G., Chen L., Xi X., Clinical and economic outcomes of hospital pharmaceutical care: A systematic review and meta-analysis, BMC Health Serv Res, 20, pp. 1-14, (2020)
38. Action Programme on Essential Drugs and Vaccines, Good Pharmacy Practice (GPP) in Community and hos­pital Settings, 1, pp. 1-11, (1996)
39. Aguiar K., Santos J., Cambrussi M.C., Picolotto S., Carneiro M.B., Patient Safety and the Value of Pharmaceutical Intervention in a Cancer Hospital, 16, pp. 1-7, (2018)
40. Brilli R.J., Spevetz A., Branson R.D., Et al., Critical care delivery in the intensive care unit: Defining clinical roles and the best practice model, Crit Care Med, 29, pp. 2007-2019, (2007)
41. Haupt M.T., Bekes C.E., Brilli R.J., Carl L.C., Et al., Guidelines on critical care services and personnel: Recommendations based on a system of categorization of three levels of care, Crit Care Med, 31, pp. 2677-2683, (2003)
42. Keely J.L., American College of Physicians-American Society of inter­nal medicine. Pharmacist scope of practice, Ann Intern Med, 136, pp. 79-85, (2002)
43. Maclaren R., Devlin J.W., Martin S.J., Dasta J.F., Rudis M.I., Bond C.A., Critical care pharmacy services in United States hospitals, Ann Pharmacother, 40, pp. 612-618, (2006)
44. Preslaski C.R., Lat I., Maclaren R., Poston J., Pharmacist contributions as members of the multidisciplinary ICU team, Chest, 144, pp. 1687-1695, (2013)
45. Valle T.D., Garcia P.C., Oncology patient admission criteria in intensive care units of general care hospitals, Rev Ciênc Med, 27, pp. 73-84, (2018)
46. Jairam V., Lee V., Park H.S., Et al., Treatment-related complications of sys­temic therapy and radiotherapy, JAMA Oncol, 5, pp. 1028-1035, (2019)
47. Bos M.M.E.M., Verburg I.W.M., Dumaij I., Stouthard J., Nortier J.W.R., Richel D., Et al., Intensive care admission of cancer patients: A comparative anal­ysis, Cancer Med, 4, pp. 966-976, (2015)
48. Taconne F.S., Artigas A.A., Spring C.L., Moreno R., Sakr Y., Vincent J.R., Characteristics and outcomes of câncer patients in European ICUS, Crit Care, 13, pp. 1-10, (2009)
49. Parack S., Piggin A., Neeman T., Mitchell I., Crispin P., Davis A., Outcomes of haematology/oncology patients admitted to intensive care unit at the Camberra Hospital, Intern Med J, 44, pp. 1087-1094, (2014)
50. Charles L.S., Et al., Consensus statement on the triage of critically ill patients. Society of Critical Care Medicine Ethics Committee, JAMA, 271, pp. 1200-1203, (1994)
51. Lecuyer L., Chevret S., Thiery G., Darmon M., Schlemmer B., Azoulay E., The ICU trial: A new admission policy for cancer patients requiring mechanical ventilation, Crit Care Med, 35, pp. 808-814, (2007)
52. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F., Global cancer statistics 2020: GLOBOCAN estimates of inci­dence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, pp. 209-249, (2021)
53. Silva L.C.A., Et al., Contributions of pharmaceutical care to patients on oncological treatment, Rev Investig Bioméd, 9, pp. 216-222, (2017)
54. Richter A., Bates I., Thacker M., Et al., Impact of the introduction of a specialist critical care pharmacist on the level of pharmaceutical care provided to the critical care unit, Int J Pharm Pract, 24, pp. 253-261, (2016)
55. Mabasa V.H., Malyuk D.L., Weatherby E.M., Chan A., A standardized, structured approach to identifying drug-related problems in the inten­sive care unit, FASTHUG-MAIDENS. Can J Hosp Pharm, 64, pp. 366-369, (2011)
56. Flannery A.H., Pandya K., Laine M.E., Et al., Managing the rising costs and high drug expenditures in critical care pharmacy practice, Pharmacotherapy, 37, pp. 54-64, (2016)
57. Neufeld N.J., Elnahal S.M., Alvarez R.H., Cancer pain: A review of epide­miology, clinical quality and value impact, Future Oncol, 13, pp. 833-841, (2017)
58. Baron R., Binder A., Biniek R., Et al., Evidence and consensus based guideline for the management of delirium, analgesia, and sedation in intensive care medicine. Revision 2015 (DAS-guideline 2015) –short version, Ger Med Sci, 13, pp. 1-42, (2015)
59. Jacobi J., Fraser G.L., Coursin D.B., Et al., Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult, Crit Care Med, 30, pp. 119-141, (2002)
60. Argelia L.S., Marisol A.O., Amparito de los A.B.P., American guidelines for cancer pain management, Pain Manag, 7, pp. 287-298, (2017)
61. Kress J.P., Pohlman A.S., O'Connor M.F., Hall J.B., Daily interruption of sedative infusions in critically ill patients undergoing mechanical venti­lation, N Engl J Med, 342, pp. 1471-1477, (2000)
62. Geerts W.H., Bergqvist D., Pineo G.F., Et al., Prevention of venous throm­boembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition), Chest. 2008, 133, pp. 381-453
63. Lima I.M., Vidigal S.B., Lima N.M., Et al., Application of FASTHUG­MAIDENS mnemonic and evaluation of its impact in pharmaceutical intervention in an adult intensive care unit, Rev Bras Farm Hosp Serv Saude, 12, pp. 1-8, (2021)
64. Ely E.W., Inouye S.K., Bernard G.R., Et al., Delirium in mechanically venti­lated patients: Validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU), JAMA, 286, pp. 2703-2710, (2001)
65. Bergeron N., Dubois M.J., Dumont M., Dial S., Skrobik Y., Intensive care delirium screening checklist: Evaluation of a new screening tool, Intensive Care Med, 27, pp. 859-864, (2001)
66. Siddiqui F., Ahmed M., Abbasi S., Et al., Gastrointestinal bleeding in patients with acute respiratory distress syndrome: A National Database Analysis, J Clin Med Res, 11, pp. 42-48, (2018)
67. Krag M., Perner A., Wetterslev J., Wise M.P., Et al., Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients, Intensive Care Med, 41, pp. 833-845, (2015)
68. Hapani S., Chu D., Wu S., Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis, Lancet Oncol, 10, pp. 559-568, (2009)
69. Plummer M.P., Blaser A.R., Deane A.M., Stress ulceration: Prevalence, pathol­ogy and association with adverse outcomes, Crit Care, 18, pp. 1-7, (2014)
70. Daley R.J., Rebuck J.A., Welage L.S., Rogers F.B., Prevention of stress ulceration: Current trends in critical care, Crit Care Med, 32, pp. 2008-2013, (2004)
71. Hershey D.S., Hession S., Chemotherapy and glycemic control in patients with type 2 diabetes and cancer: A comparative case analysis, Asia Pac J Oncol Nurs, 4, pp. 224-232, (2017)
72. Bell C.M., Brener S.S., Gunraj N., Et al., Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases, JAMA, 306, pp. 840-847, (2011)
73. Bosma L.B.E., Hunfeld N.G.M., Quax R.A.M., Et al., The effect of a medica­tion reconciliation program in two intensive care units in the Netherlands: A prospective intervention study with a before and after design, Ann Intensive Care, 8, pp. 1-19, (2018)
74. Manias E., Williams A., Liew D., Interventions to reduce medication errors in adult intensive care: A systematic review, Br J Clin Pharmacol, 74, pp. 411-423, (2012)
75. Santos J.P., Azevedo R.M.H.S., Araujo P.L., Et al., Pharmaceutical care in oncology UTI, Braz J Hea, 3, pp. 5697-5704, (2020)
76. Lin Q., Wang G., Ma G., Et al., The role of pharmaceutical care in the oncology department, Eur J Hosp Pharm, 22, pp. 128-131, (2015)
77. Chagastelles P.C., Nardi N.B., Biology of stem cells: An overview, Kidney Int Suppl, 1, pp. 63-67, (2011)
78. Hawley R.G., Ramezani A., Hawley T.S., Hematopoietic Stem Cells, 365, pp. 149-179, (2006)
79. Henig I., Zuckerman T., Hematopoietic stem cell transplantation –50 years of evolution and future perspectives, Rambam Maimonides Med J, 5, pp. 1-15, (2014)
80. Park M., Seo J.J., Role of HLA in hematopoietic stem cell transplantation, Bone Marrow Res, 20, pp. 1-7, (2012)
81. Lennard A.L., Jackson G.H., Topic in review: Stem cell transplantation, West J Med, 175, pp. 42-46, (2001)
82. Balassa K., Danby R., Rocha V., Haematopoietic stem cell transplants: Principles and indications, Br J Hosp Med, 80, pp. 33-39, (2019)
83. Choo S.Y., The HLA system: Genetics, immunology, clinical testing, and clinical implications, Yonsei Med J, 48, pp. 11-23, (2007)
84. Gahrton G., Svensson H., Bjorkstrand B., Et al., Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation, Bone Marrow Transplant, 24, pp. 741-745, (1999)
85. Bayraktar U.D., Nates J.L., Intensive care outcomes in adult hematopoietic stem cell transplantation patients, World J Clin Oncol, 7, pp. 98-105, (2016)
86. Randolph B.V., Ciurea S.O., What the intensivist needs to know about hematopoietic stem cell transplantation?, Oncol Crit Care Springer International Publishing, 1, pp. 1531-1546, (2019)
87. Jantunen E., Itala M., Lehtinen T., Et al., Early treatment-related mortality in adult autologous stem cell transplant recipients: A nation-wide survey of 1482 transplanted patients, Eur J Haematol, 76, pp. 245-250, (2006)
88. Bulley S.R., Strahm B., Doyle J., Dupuis L.L., Defibrotide for the treatment of hepatic veno-occlusive disease in children, Pediatr Blood Cancer, 48, pp. 700-704, (2007)
89. Bayraktar U.D., Shpall E.J., Liu P., Ciurea S.O., Rondon G., De Lima M., Cardenas-Turanzas M., Price K.J., Champlin R.E., Nates J.L., Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mor­tality and survival in patients who received allogeneic transplantation admitted to the intensive care unit, J Clin Oncol, 31, pp. 4207-4214, (2013)
90. Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., Storer B., Hematopoietic cell transplantation (HCT)-specific comorbid­ity index: A new tool for risk assessment before allogeneic HCT, Blood, 106, pp. 2912-2919, (2005)
91. Saillard C., Blaise D., Mokart D., Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: Reappraisal of actual prognosis, Bone Marrow Transplant, 51, pp. 1050-1061, (2016)
92. Justiz A.A., Vaillant R.V., Zito P.M., Immediate hypersensitivity reactions, Immunotoxicol Risk Assess, 1, pp. 155-171, (2006)
93. Kanji S., Chant C., Allergic and hypersensitivity reactions in the inten­sive care unit, Crit Care Med, 38, pp. 162-168, (2010)
94. Marwa K., Kondamudi N.P., Type IV hypersensitivity reaction, Statpearls Publishing, 2, pp. 1-8, (2020)
95. Justiz Vaillant A.A., Zito P.M., Immediate hypersensitivity reactions, Statpearls Publishing, 1, pp. 1-10, (2018)
96. Ericson-Neilsen W., Kaye A.D., Steroids: Pharmacology, complications, and practice delivery issues, Ochsner J, 14, pp. 203-207, (2014)
97. Liu D., Ahmet A., Ward L., Krishnamoorthy P., Mandelcorn E.D., Leigh R., Brown J.P., Cohen A., Kim H., A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy, Allergy Asthma Clin Immunol, 9, pp. 1-25, (2013)
98. Buchman A.L., Side effects of corticosteroid therapy, J Clin Gastroenterol, 33, pp. 289-294, (2001)
99. Schacke H., Docke W.D., Asadullah K., Mechanisms involved in the side effects of glucocorticoids, Pharmacol Ther, 96, pp. 23-43, (2002)
100. Vatti R.R., Ali F., Teuber S., Chang C., Gershwin M.E., Hypersensitivity reactions to corticosteroids, Clin Rev Allergy Immunol, 47, pp. 26-37, (2014)
101. Patel A., Bahna S.L., Immediate hypersensitivity reactions to corticoste­roids, Ann Allergy Asthma Immunol, 115, pp. 178-182, (2015)
102. Watkins T., Surowiecka M.K., McCullough J., Transfusion indications for patients with cancer, Cancer Control, 22, pp. 38-46, (2015)
103. Bayer W.L., Bodensteiner D.C., Tilzer L.L., Adams M.E., Use of platelets and other transfusion products in patients with malignancy, Semin Thromb Hemost, 18, pp. 380-391, (1992)
104. Montenegro H., World Health Organisation: Global Status Report on Blood Safety and Availability, (2016)
105. Iqbal N., Haider K., Sundaram V., Radosevic J., Burnouf T., Seghatchian J., Goubran H., Red blood cell transfusion and outcome in cancer, Transfus Apher Sci, 56, pp. 287-290, (2017)
106. Hogshire L., Carson J.L., Red blood cell transfusion: What is the evidence when to transfuse?, Curr Opin Hematol, 20, pp. 546-551, (2013)
107. Sapiano M.R.P., Savinkina A.A., Ellingson K.D., Haass K.A., Baker M.L., Henry R.A., Berger J.J., Kuehnert M.J., Basavaraju S.V., Supplemental find­ings from the National Blood Collection and Utilization Surveys, 2013 and 2015, Transfusion, 57, pp. 1599-1624, (2017)
108. Velasquez J.F., Cata J.P., Transfusions of blood products and cancer out­comes, Rev Esp Anestesiol Reanim, 62, pp. 461-467, (2015)
109. Vincent J.L., Jaschinski U., Wittebole X., Lefrant J.Y., Jakob S.M., Almekhlafi G.A., Pellis T., Tripathy S., Rubatto Birri P.N., Sakr Y., Worldwide audit of blood transfusion practice in critically ill patients, Crit Care, 22, pp. 1-9, (2018)
110. Vlaar A.P., Oczkowski S., De Bruin S., Et al., Transfusion strategies in non­bleeding critically ill adults: A clinical practice guideline from the European Society of Intensive Care Medicine, Intensive Care Med, 46, pp. 673-696, (2020)
111. Hendrickson J.E., Tormey C.A., Red blood cell antibodies in hematology/ oncology patients: Interpretation of immunohematologic tests and clini­cal significance of detected antibodies, Hematol Oncol Clin North Am, 30, pp. 635-651, (2016)
112. Tas F., Eralp Y., Basaran M., Sakar B., Alici S., Argon A., Bulutlar G., Camlica H., Aydiner A., Topuz E., Anemia in oncology practice: relation to diseases and their therapies, Am J Clin Oncol Cancer Clin Trials, 25, pp. 371-379, (2002)
113. Abdel-Razeq H., Saadeh S.S., Malhis R., Yasser S., Abdulelah H., Eljaber R., Kleib A., Ismael R., Treatment of anemia in cancer patients undergo­ing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents, Ther Adv Med Oncol, 12, pp. 1-9, (2020)
114. Chantepie S.P., Mear J.B., Parienti J.J., Et al., Blood transfusion in hemato­logic intensive care unit, Transfusion, 57, pp. 296-302, (2017)
115. Leal-Noval S.R., Munoz-Gomez M., Jimenez-Sanchez M., Cayuela A., Leal-Romero M., Puppo-Moreno A., Enamorado J., Arellano-Orden V., Red blood cell transfusion in non-bleeding critically ill patients with moderate anemia: Is there a benefit?, Intensive Care Med, 39, pp. 445-453, (2013)
116. Hebert P.C., Wells G., Blajchman M.A., Marshall J., Martin C., Pagliarello G., Tweeddale M., Schweitzer I., Yetisir E., A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care, N Engl J Med, 340, pp. 409-417, (1999)
117. Webert K.E., Cook R.J., Couban S., Carruthers J., Lee K.-A., Blajchman M.A., Lipton J.H., Brandwein J.M., Heddle N.M., A multicenter pilot- randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemother­apy for acute leukemia or stem cell transplantation, Transfusion, 48, pp. 81-91, (2008)
118. Carson J.L., Stanworth S.J., Roubinian N., Fergusson D.A., Triulzi D., Doree C., Hebert P.C., Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion, Cochrane Database Syst Rev, 10, pp. 1-118, (2016)
119. Carson J.L., Carless P.A., Hebert P.C., Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion, JAMA, 309, pp. 83-84, (2013)
120. Carson J.L., Brooks M.M., Abbott J.D., Et al., Coronary artery disease liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease, Am Heart J, 165, pp. 964-971, (2013)
121. Fleming A., On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B, Bull World Health Organ, 79, pp. 780-790, (1929)
122. Tverdek F.P., Rolston K.V., Chemaly R.F., Antimicrobial stewardship in patients with cancer, Pharmacotherapy, 32, pp. 722-734, (2012)
123. Basaran N.C., Karaagaoglu E., Hascelik G., Tanriover M.D., Akova M., Prospective evaluation of infection episodes in cancer patients in a tertiary care academic center: Microbiological features and risk factors for mortality, Turkish J Hematol, 33, pp. 311-319, (2016)
124. Srinivasan A., Wang C., Srivastava D.K., Burnette K., Shenep J.L., Leung W., Hayden R.T., Timeline, epidemiology, and risk factors for bacterial, fun­gal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 19, pp. 94-101, (2013)
125. Rolston K.V.I., Infections in cancer patients with solid tumors: A review, Infect Dis Ther, 6, pp. 69-83, (2017)
126. Blennow O., Ljungman P., Infections in hematology patients, Concise Guide to Hematology, pp. 503-518, (2019)
127. Zembower T.R., Epidemiology of infections in cancer patients, Cancer Treat Res, 161, pp. 43-89, (2014)
128. Napolitano L.M., Edmiston C.E., Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update, Surgery, 162, pp. 325-348, (2017)
129. Chopra T., Alangaden G.J., Chandrasekar P., Clostridium difficile infec­tion in cancer patients and hematopoietic stem cell transplant recipients, Expert Rev Anti-Infect Ther, 8, pp. 1113-1119, (2010)
130. Abughanimeh O., Qasrawi A., Kaddourah O., Al Momani L., Abu Ghanimeh M., Clostridium difficile infection in oncology patients: Epi­demiology, pathophysiology, risk factors, diagnosis, and treatment, Hosp Pract, 46, pp. 266-277, (2018)
131. Sipsas N.V., Kontoyiannis D.P., Invasive fungal infections in patients with cancer in the intensive care unit, Int J Antimicrob Agents NIH Public Access, 39, pp. 464-471, (2012)
132. Rello J., Sarda C., Mokart D., Arvaniti K., Akova M., Tabah A., Azoulay E., Antimicrobial stewardship in hematological patients at the intensive care unit: A global cross-sectional survey from the nine-i investigators network, Eur J Clin Microbiol Infect Dis, 39, pp. 385-392, (2020)
133. Montassier E., Batard E., Gastinne T., Potel G., De La Cochetiere M.F., Recent changes in bacteremia in patients with cancer: A systematic review of epidemiology and antibiotic resistance, Eur J Clin Microbiol Infect Dis, 32, pp. 841-850, (2013)
134. Leekha S., Terrell C.L., Edson R.S., General principles of antimicrobial therapy, Mayo Clin Proc Elsevier, 15, pp. 156-167, (2011)
135. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H., The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting, Chest, 118, pp. 146-155, (2000)
136. Dellit T.H., Owens R.C., McGowan J.E., Et al., Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimi­crobial stewardship, Clin Infect Dis, 44, pp. 159-177, (2007)
137. Radbruch L., De Lima L., Knaul F., Et al., Redefining palliative care-a new consensus-based definition, J Pain Symptom Manag, 60, pp. 754-764, (2020)
138. Etkind S.N., Bone A.E., Gomes B., Lovell N., Evans C.J., Higginson I.J., Murtagh F.E.M., How many people will need palliative care in 2040? Past trends, future projections and implications for services, BMC Med, 15, pp. 1-10, (2017)
139. Rietjens J.A.C., Sudore R.L., Connolly M., Et al., Definition and recommen­dations for advance care planning: An international consensus supported by the European Association for Palliative Care, Lancet Oncol, 18, pp. 543-551, (2017)
140. McCaughan D., Roman E., Smith A.G., Garry A.C., Johnson M.J., Patmore R.D., Howard M.R., Howell D.A., Palliative care specialists’ perceptions concerning referral of haematology patients to their services: Findings from a qualitative study, BMC Palliat Care, 17, pp. 1-11, (2018)
141. Delgado-Guay M.O., Parsons H.A., Li Z., Palmer L.J., Bruera E., Symptom distress, interventions, and outcomes of intensive care unit cancer patients referred to a palliative care consult team, Cancer, 115, pp. 437-445, (2009)
142. Leblanc T.W., El-Jawahri A., When and why should patients with hema­tologic malignancies see a palliative care specialist?, Hematol (United States), 2015, pp. 471-478, (2015)
143. Temel J.S., Greer J.A., Muzikansky A., Et al., Early palliative care for patients with metastatic non–small-cell lung cancer, N Engl J Med, 363, pp. 733-742, (2010)
144. Romano A.M., Gade K.E., Nielsen G., Havard R., Harrison J.H., Barclay J., Stukenborg G.J., Read P.W., Blackhall L.J., Dillon P.M., Early palliative care reduces end-of-life intensive care unit (ICU) use but not ICU course in patients with advanced cancer, Oncologist, 22, pp. 318-323, (2017)
145. Connor S.R., Pyenson B., Fitch K., Spence C., Iwasaki K., Comparing hos­pice and nonhospice patient survival among patients who die within a three-year window, J Pain Symptom Manag, 33, pp. 238-246, (2007)
146. Yun Y.H., Lee M.K., Kim S.Y., Et al., Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of termi­nally ill patients with cancer: Prospective cohort study, J Clin Oncol, 29, pp. 2474-2480, (2011)
147. Smith T.J., Temin S., Alesi E.R., Et al., American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care, J Clin Oncol, 30, pp. 880-887, (2012)